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This year’s LaskerDeBakey Clinical Research Award goes to James Allison for discovering that
antibody blockade of the T cell molecule CTLA-4 unleashes the body’s immune response against
malignant tumors. This has led to development of multiple ‘‘immune checkpoint therapies’’ that
are prolonging and saving the lives of thousands of cancer patients.Most advances in cancer therapy have
come incrementally and have often been
limited to individual types of malig-
nancies. Early approaches that focused
on surgical intervention were then supple-
mented or replaced by radiation therapy
and, subsequently, chemotherapy during
the last century. With the elucidation of
signaling pathways that are dysregulated
in cancers, ‘‘targeted therapies,’’ most
notably protein kinase inhibitors, were
successfully adopted during the past
two decades. However, despite these
advances, durable responses to therapy
for most metastatic or inoperable malig-
nancies remain rare.
For this reason, it has long been the
dream of physicians to be able to harness
the body’s own immune defenses to elim-
inate neoplastic cells, much as they elim-
inate invading pathogens. Even before
the components making up the immune
system were known, physicians noted
patients whose solid tumors regressed
and even disappeared after they suffered
skin infections such as erysipelas, typi-
cally caused by Streptococci. In famous
experiments in the late 19th century, Wil-
liam Coley injected bacterial extracts
into multiple patients suffering from bone
or soft tissue sarcomas and over several
decades reported responses or complete
remissions in a substantial fraction of
them. Unfortunately, Coley never con-
ducted controlled trials, and those who
succeeded him were unable to garner
the needed support to continue testing
the ‘‘Coley toxins,’’ particularly with the
enthusiasm for radiotherapy and chemo-
therapy at that time.
Only a few immunologists continued
to work on cancer therapies after the1186 Cell 162, September 10, 2015 ª2015 Elmid-1950’s. Even so, there were some
notable successes, such as the anti-
tumor response elicited by local injection
of the BCG mycobacterium in bladder
cancers and the sporadic successes
of IL-2 therapy in melanoma and renal
cancer patients. With the spectacular
advances in our understanding of T cell
immunity and antigen presentation over
the past 30 years came the possibility
that tumor vaccines could be engineered
to elicit protective or therapeutic re-
sponses. Yet widespread skepticism
remained within the oncology and immu-
nology communities as to whether the
body’s immune responses could be
mobilized to selectively kill tumor cells.
Only a few brave souls dared to enter
the field of tumor immunology, particularly
during a period when most advances in
immunology were being made at the level
of molecular and cell mechanisms.
It is fair to say that the attitude of physi-
cians and scientists alike toward cancer
immunotherapy has changed dramati-
cally during the past 5 years. The stunning
successes in treating cancers with anti-
CTLA-4 and anti-PD1 ‘‘immune check-
point therapies’’ have spawned newfound
optimism that targeting of additional im-
mune pathways and optimization of drug
regimens will be effective in numerous
cancers and in larger proportions of pa-
tients. It is rare that such a sea change
can be traced to any one individual, but
the advent of checkpoint therapy would
have been highly unlikely without the
efforts of James Allison, the recipient
of this year’s LaskerDeBakey Clinical
Research Award.
Allison’s critical insight built upon the
recent elucidation of how T lymphocytessevier Inc.become activated and target cells for
killing. He recognized that a recently
discovered cell surface receptor called
CTLA-4, which turns on after T cell activa-
tion to help shut off the response and
prevent excessive inflammation, could
be targeted therapeutically to potentiate
the cytolytic activity of tumor-infiltrating
T cells. His studies confirmed that tumor-
targeting T cells are not uncommon but
are often disabled in tumors and hence
need to be mobilized to become effective
fighters against cancerous tissues.
Allison performed the seminal experi-
ments showing that CTLA-4 blockade
unleashes the body’s immune response
against multiple poorly immunogenic tu-
mors and then embarked on a relentless
campaign to find clinical partners who
would translate the therapeutic approach
to cancer patients. He had to overcome
the profound skepticism among physi-
cians that had developed over many
decades, and it is a testament to his sin-
gle-minded zeal that we are celebrating
the dawn of a new age in cancer thera-
pies. While this prize has been awarded
for a discovery that has resulted in
immense clinical benefit, it is based on
work deeply rooted in basic science
research, much by Allison himself, and
is a showcase for the indispensability of
animal research in advancing human
health. Many individuals have contributed
to our understanding of how T cells are
activated, but Jim Allison saw the poten-
tial of targeting CTLA-4 to treat cancer,
helped forge the needed collaboration
with an industry partner, and advocated
passionately and ultimately successfully
for translation to patients. The clinical
studies themselves required courage on
Figure 1. Activation of Anti-Tumor Cytotoxic T Cells by Blockade of CTLA-4
Proposedmechanisms for the activity of anti-CTLA-4 antibody in releasing inhibition of tumor cell killing by
CD8+ T cells. (Pathway 1) Indirect mechanism through inhibition of regulatory T cell (Treg) accumulation in
tumors, which requires binding of antibody to Fc receptor on innate immune cells and is mediated by
antibody-dependent cellular cytotoxicity. (Pathway 2) Direct activity on cytotoxic T lymphocytes through
inhibition of CTLA-4 interaction with B7-1 and B7-2 on antigen-presenting dendritic cells, thereby
increasing CD28 co-stimulatory activity and/or reducing CTLA-4 inhibitory signaling. Note that tumor
peptide antigen is cross-presented to CTL by dendritic cells, and direct interaction of T cells with tumor
cells may result in anergy through the T cell receptor (TCR).the part of companies and clinical oncolo-
gists, who ventured into uncharted terri-
tory by developing new criteria to evaluate
responses to the therapy.
Laying the Groundwork
The discovery of CTLA-4 as a therapeutic
target in cancer hinged on earlier work
that identified T cell surface molecules
and their cognate ligands that cooperate
with the antigen receptor signaling ma-
chinery. The discovery of the T cell anti-
gen receptor (TCR) in the early 1980’s,
an endeavor to which Allison contributed
by identifying a clonally restricted hetero-
dimer in a T cell lymphoma, launched ef-
forts toward understanding how antigen
recognition results in T cell activation.
It was soon discovered that antibody
stimulation of the TCR or its associated
signaling machinery, the CD3 complex,
was sufficient to activate immortalized
cell lines in which much of the early
biochemical work on signal transduction
was carried out. However, proliferation
of primary T cells required a second signal
distinct from that transmitted throughTCR/CD3. In their influential ‘‘two-signal
hypothesis’’ in 1970, Bretcher and Cohn
had postulated that activation of antibody
production by B lymphocytes requires
signaling through both the membrane-
bound antigen receptor and an accessory
receptor and that cells receiving the anti-
genic signal alone would be rendered
un-responsive or tolerant.
Ron Schwartz and his colleagues found
that such a mechanism indeed operates
in T lymphocyte activation. Pulsing anti-
gen-presenting cells (APCs) with peptide
antigen resulted in IL-2 production and
proliferation of T cells bearing receptors
specific for that peptide bound to major
histocompatibility complex (MHC) mole-
cules. By contrast, exposing antigen-
specific T cells to MHC/antigen in lipid
bilayers or in chemically fixed APCs
induced T cell paralysis, such that they
failed to proliferate upon subsequent
exposure to unfixed cells (Jenkins and
Schwartz, 1987). This phenomenon,
known as anergy, could be overcome if
non-antigen-pulsed APCs, even of mis-
matched MHC, were included in additionCell 162, Septo the chemically modified APCs. These
experiments were the first to provide
convincing evidence that full T cell acti-
vation requires engagement of both TCR
and a second non-antigen-specific ‘‘co-
stimulatory’’ pathway, activated by a
ligand on a heterologous cell. These
results attracted considerable attention,
as they validated the ‘‘two-signal’’ hy-
pothesis and also suggested a mecha-
nism for tolerance to self-antigen when
recognized by T cells in the absence of
co-stimulation.
The Schwartz studies sparked con-
certed efforts to identify the co-stimula-
tory molecule. These culminated in
studies by Marc Jenkins using human
cells (Jenkins et al., 1991) and by Allison
using mouse models (Harding et al.,
1992), reporting that an immunoglobulin
superfamily member, CD28, had the
properties that would be expected of
the co-stimulatory molecule. Specifically,
crosslinked monoclonal antibodies
against CD28 rescued IL-2 production
and T cell proliferation when antigen was
presented on fixed APCs, whereas mono-
valent antibodies (Fab) against CD28
rendered the T cells anergic after antigen
presentation by unfixed APCs. Shortly
thereafter, B7-1 (CD80) and B7-2 (CD86)
were discovered to be CD28 ligands ex-
pressed by APCs; blocking antibodies
against B7-1 inhibited T cell stimulation
by antigen-pulsed APCs (Figure 1).
Together, these results presented a
pleasing explanation for co-stimulation.
However, this was not the end of the
story.
CTLA-4 Puts the Brakes on the
T Cell Response
During the 1980’s, new technologies for
gene cloning, including subtractive hy-
bridization and gene transfer, enabled
identification of the genes encoding the
TCR subunits and multiple other lympho-
cyte surface glycoproteins. Among these
was CTLA-4, cloned by Pierre Golstein
from a subtractive cDNA library produced
from a CD8 lineage T cell clone. CTLA-4 is
an immunoglobulin superfamily member
whose locus is closely linked to that of
CD28 and whose protein sequence bears
substantial homology to CD28, particu-
larly in its extracellular domain. Whereas
CD28 is expressed constitutively at the
surface of T cells, CTLA-4 expressiontember 10, 2015 ª2015 Elsevier Inc. 1187
and translocation to the cell surface are
induced only after activation of T cells.
These findings set in motion a number
of efforts to manipulate CTLA-4 and
thereby regulate T cell function. Peter
Linsley, Jeffrey Ledbetter, and colleagues
at Bristol-Myers Squibb (BMS) generated
a CTLA-4-Ig fusion protein and showed
that it bound to both B7-1 and B7-2 with
substantially greater affinity than CD28
and was able to block T cell responses
to allogeneic cells. Jeff Bluestone’s group
additionally showed that CTLA-4-Ig was
effective when administered to mice,
blocking allograft rejection, and he subse-
quently championed its utility for autoim-
mune disease therapy. These and other
studies led BMS to develop CTLA-4-Ig
as Orencia, which is used clinically to treat
rheumatoid arthritis.
CTLA-4 was initially proposed to serve
as a co-stimulatory molecule, much like
CD28, since an anti-CTLA-4 antibody
further enhanced the anti-CD28-medi-
ated proliferative effect. However, Blue-
stone and colleagues, followed soon
thereafter by Allison, found that, unlike
anti-CD28 Fabs, anti-CTLA-4 monovalent
Fab fragments actually enhanced T cell
responses to allogeneic cells, while
optimal crosslinking with full-length anti-
CTLA-4 antibodies inhibited responses
to anti-CD3/CD28. Both groups con-
cluded that CTLA-4 expressed in acti-
vated T cells interacts with B7 ligands
to compete for CD28 binding and also
transduces a negative signal that inhibits
IL-2 production and T cell proliferation,
thus preventing over-activation of the im-
mune system (Krummel and Allison, 1995;
Walunas et al., 1994) (Figure 1). This
conclusion was reinforced by the dra-
matic phenotype of Ctla4 knockout
mice. Unlike CD28-deficient mice, which
have relatively subtle defects in their
peripheral T cells, CTLA-4-deficient mice
developed lethal lymphoproliferation
within their first weeks of life, confirming
that CTLA-4 has a key role in restraining
T cell immune responses.
Targeting CTLA-4 in Cancer
Immunologists have long tried to develop
therapeutic vaccines to target tumor-
specific antigens, but this endeavor has
been largely unsuccessful; even in mouse
models, most tumors elicit only weak and
ineffective immune responses. Although1188 Cell 162, September 10, 2015 ª2015 Eltumor antigens can be presented to
T cells by dendritic cells with co-stimula-
tory capacity (a phenomenon known as
cross-priming), this process is inefficient
and may even be thwarted by pre-emp-
tive induction of anergy when infiltrating
cytotoxic T cells interact with tumor cells
directly and receive only the TCR signal
(Figure 1). The discovery of the CD28-B7
co-stimulation axis raised the prospect
that providing co-stimulatory capacity to
tumors, which typically lack expression
of B7-1 and B7-2, would enhance their
immunogenicity and make them more
susceptible to immune attack. Indeed,
experiments by Lindsey and Allison
showed that transfection of multiple types
of tumor cells with B7-1 resulted in CD8
T cell-mediated elimination of the tumors
after their implantation in mice. Remark-
ably, exposure of animals to B7-express-
ing tumors protected them from challenge
with the same tumor lacking the co-stim-
ulatory ligand. Enhanced co-stimulation
could thus augment durable specific
anti-tumor T cell responses.
These results, coupled with the new in-
sights into the role of CTLA-4 as an inhib-
itory molecule, led Allison to hypothesize
that blocking CTLA-4’s interaction with
B7-1 or B7-2 might release the ‘‘brake’’
on the CD8 T cell response, resulting in
tumor killing. Consistent with this hypo-
thesis, a pivotal paper by Leach, Krum-
mel, and Allison, published in 1996,
showed that anti-CTLA-4 administration
resulted in dramatic reduction in the
growth of some implanted tumors, even
when these antibodies were administered
after the tumors had expanded to a
substantial size (Leach et al., 1996). More-
over, anti-CTLA-4-induced rejection of
the tumor resulted in immunological
memory, leading to long-lived immunity
to secondary tumor challenge.
The precise mechanism by which anti-
CTLA-4 antibody enhances killing of
tumor cells and elicits a durable cytotoxic
T cell response is not yet fully defined
(Figure 1). Although the antibody inter-
feres with the ‘‘braking’’ function of
CTLA-4 in cytotoxic T cells, there is evi-
dence that it also depletes intratumoral
regulatory T cells, thus releasing inhibition
of tumor-killing CD8+ T cells (Selby et al.,
2013). However CTLA-4 blockade oper-
ates, Allison’s 1996 paper and several
follow-up studies made it clear that itsevier Inc.could be effective for killingmany different
types of tumors, alone or more often in
combination with other therapies. For
example, Allison and his colleagues
demonstrated that CTLA-4 blockade,
which they named ‘‘immune checkpoint
therapy,’’ was rendered more effective in
animal models of a variety of tumors
when combined with delivery of cyto-
kines, with vaccination using irradiated
tumor cells, or with chemotherapy or
radiation therapy, which can result in
stronger cross-priming of T cells by tumor
antigens presented on tumor-resident
myeloid cells. Together, these preclinical
studies convinced Allison that antibody
targeting of human CTLA-4 could be
effective in the treatment of patients, and
he set out to bring this approach into the
clinic.
The Winding Path to the Success of
Ipilimumab
The successful treatment of multiple
mouse tumors with anti-CTLA-4 im-
pressed immunologists, but the perceived
failure of many earlier immune-based
therapies created a very high bar for
advancing immune checkpoint therapy
to the clinic. Allison waged a campaign
to convince funding agencies and phar-
maceutical companies to move forward
with clinical trials. Alan Korman, an immu-
nologist at Nexstar Pharmaceuticals,
a biotechnology company in Colorado,
began working on an anti-human CTLA-4
antibody after hearing from Allison about
the exciting results in mouse tumor
models, and Nexstar licensed the
CTLA-4 blockade technology from UC
Berkeley in 1998. They then sub-licensed
the technology to Medarex, a biotech-
nology company that had recently ac-
quired GenPharm, a company led by
Nils Lonberg specializing in producing
human monoclonal antibodies in geneti-
cally manipulated mice.
Korman soon moved to Medarex, and
he and Lonberg set to work developing
fully human antibodies specific for human
CTLA-4. One of these antibodies, MDX-
010, was chosen for further development
and was shown to be effective in ma-
caques, potentiating antibody responses
to immunogens and displaying no
apparent autoimmune manifestations in
that species (Keler et al., 2003). In 2000,
Medarex began phase 1 studies with
Allison and clinical investigators at the
University of California, San Francisco,
evaluating patients with hormone-refrac-
tory prostate cancer andmetastatic mela-
noma. Two out of 17 melanoma patients
exhibited durable responses, and the
therapy was well tolerated, which encour-
aged further studies at the National Can-
cer Institute, led by Steven Rosenberg,
administering MDX-010 (later named Ipili-
mumab) to advanced melanoma patients,
who also received a melanoma antigen
vaccine. Immune cells infiltrated the
tumors, and cancer regression was
observed in 10%–20%of patients in small
cohorts. However, there were severe
inflammatory manifestations, including
colitis, hepatitis, and hypophysitis, which
required steroid therapy.
In 2004, Medarex initiated a collabora-
tion with BMS to expand anti-CTLA-4
clinical trials, but the early optimism for
the promise of the therapy was mixed
with fear that the FDAwould stop the trials
due to the adverse side effects and its un-
clear efficacy. At that time, the response
of solid tumors to any therapy was based
on criteria developed during the era of
chemotherapy, which focused on reduc-
tion in tumor size within a limited period
of time post-administration. Accordingly,
increases in tumor size or the appearance
of new lesions during initial trials of anti-
CTLA-4 were interpreted to indicate pro-
gressive disease and treatment failure.
Nevertheless, some astute clinicians
noted that many patients classified as
having progressive disease went on to
have favorable long-term outcomes. Dur-
ing 2004 and 2005, clinical workshops
were convened to discuss how to classify
treatment failures versus efficacy in
patients receiving immune therapy. One
of the conclusions of these discussions
was that ‘‘responses to immune therapies
may occur after conventional progressive
disease’’ (Hoos et al., 2007). The
Medarex/BMS clinical team and their
academic collaborators, led by Jedd
Wolchok, Axel Hoos, Steven O’Day, and
Stephen Hodi, published an influential pa-
per in which WHO criteria for assessment
of clinical efficacy were reconfigured as
immune-related response criteria (irRC)
(Wolchok et al., 2009). By that time, how-
ever, Pfizer, which had also initiated an
anti-CTLA-4 clinical program with their
antibody, Tremelimumab, had alreadydropped out after perceived failure of a
phase 3 trial. To their credit, the Med-
arex-BMS team persevered in the face
of this challenge, particularly after the
FDA refused to approve Ipilimumab
following a dose-ranging trial that had
questionable efficacy and after BMS
acquired Medarex in 2009.
The turning point came with a phase 3
trial comparing Ipilimumab to amelanoma
peptide vaccine in metastatic melanoma
patients who had the HLA A0201 allele
(Hodi et al., 2010). Key to the success of
the study was the decision to evaluate
overall survival rather than response
rate, and in the large study, Ipilimumab
monotherapy resulted in more than 20%
long-term survival. Significantly, among
those who survived 24 months, there
were very few relapses (Hodi et al.,
2010), and we now know based on 10
years of follow-up data that about 20%
of metastatic melanoma patients are
cured with this single agent—a remark-
able outcome considering that almost all
of those patients would have died with
conventional therapy within 1–2 years.
The success of this trial led the FDA to
finally approve Ipilimumab for the treat-
ment of metastatic melanoma in 2011.
Targeting of PD-1 and PD-L1
At around the time when Ipilimumab was
being considered for FDA approval, re-
newed excitement about immune check-
point therapy came from clinical studies
targeting a second immune inhibitory
molecule, PD-1. PD-1 was discovered
by Tasuku Honjo in 1992 in a screen for
genes expressed during programmed
cell death of a T cell hybridoma (Ishida
et al., 1992). PD-1 disruption in mice re-
sulted in inflammatory disease, including
a lupus-like syndrome and cardiomyopa-
thy. Although PD-1 is expressed more
widely than CTLA-4, its major activity is
thought to be in T cells, where it is upregu-
lated during immune responses and
transmits inhibitory signals upon interac-
tion with its ligands, PD-L1 and PD-L2.
Unlike CTLA-4, which functions mainly
during primary immune responses, PD-1
signaling results in ‘‘exhaustion’’ of acti-
vated T cells, an anergic-like state that is
thought to be due to a shift in the utiliza-
tion of metabolic substrates (Pauken and
Wherry, 2015). Antibody blockade of
PD-1 was shown to enhance anti-tumorCell 162, Sepand anti-viral responses in animal models,
suggesting that this could be another im-
mune checkpoint target for cancer.
The Medarex scientists began a pro-
gram to develop anti-human PD-1 anti-
bodies in the early 2000’s (Wang et al.,
2014). This program followed closely on
the heels of CTLA-4, and early clinical
trials showed promising results in meta-
static melanoma, non-small-cell lung
cancer (NSCLC), and renal cell carci-
noma, with much milder adverse effects
than CTLA-4 blockade (Topalian et al.,
2012). Schering Plough also acquired
an anti-PD1 antibody developed by
Organon, and this was introduced into
the clinic as Pembrolizumab, after the
company was acquired by Merck, and
was approved by the FDA for treating
advanced melanoma in 2014. The BMS
drug, Nivolumab, was approved very
shortly thereafter.
Future Prospects for Immune
Checkpoint Therapy
Even though the initial CTLA-4 data were
eventually accepted by immunologists
and medical oncologists, this acceptance
was grudging, because melanoma was
thought to be an ‘‘immunologically
responsive’’ tumor; indeed, melanomas
occasionally regress by themselves. The
finding that anti-PD-1 had activity against
NSCLC was a dramatic refutation of this
notion and sparked the enthusiasm seen
today for immune therapy. During the
past 2–3 years, outcomes of clinical trials
with Ipilimumab and the PD-1 or PD-L1 in-
hibitors, alone or in combination, have
dominated the news coming out of clinical
oncology meetings. Combination therapy
blocking both checkpoint pathways has
been particularly effective, with response
rates in advanced melanoma of over
80%.
The biopharmaceutical industry has
embraced immunotherapy with unbridled
enthusiasm, and acquisitions and
licensing deals for new approaches are
in the news almost every week. New
checkpoint targets, including negative
regulators of both adaptive and innate
immune cells, are being actively inves-
tigated, as are combination therapies
with cytokines, co-stimulatory molecules,
antigen vaccines, and small-molecule
modulators of signaling pathways and
enzymes. The control of many cancerstember 10, 2015 ª2015 Elsevier Inc. 1189
will likely require combining immune
therapies with targeted therapies, con-
ventional chemotherapy, and radiation
therapy to maximize efficacy and limit
toxicity.
There are obviously many questions
that remain to be answered, including
why only certain tumors are effectively
targeted by immune checkpoint therapy
and why some patients but not others
respond to the therapy. Answers to these
and other questions will require sequenc-
ing of tumor genomes to elucidate the role
of mutations and neo-antigens, combined
with sophisticated monitoring of the
immune cells and the microenvironments
within different types of tumors.
James Allison appreciated early on the
importance of immune monitoring in pa-
tients receiving immune checkpoint ther-
apy. Indeed, in order to be closer to the
patients, their invaluable tumor-derived
biological specimens, and the clinicians
providing treatment, hemoved his labora-
tory from the University of California at
Berkeley to the Memorial Sloan Kettering
Cancer Center in 2004 and, subsequently,
to the MD Anderson Cancer Center. This
year’s well-deserved Lasker Prize recog-
nizes the impact of Allison’s vision on1190 Cell 162, September 10, 2015 ª2015 Elthe many thousands of cancer patients
already benefitting from the clinical
development of immune checkpoint in-
hibitors. The change in attitude of clinical
oncologists and immunologists toward
the place of immune modulation in
combatting cancer guarantees that there
will be many exciting advances in im-
mune-based therapies in the years ahead.
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